Adagene to Present at Investor and Scientific Conferences in September
- Adagene's CEO and President of R&D,Dr. Peter Luo,participating in SITC webinar on September 22 focused on essential role of Treg depletion for anti-CTLA-4 therapies -
SAN DIEGO and SUZHOU,China,Sept. 8,2023 -- Adagene Inc. ("Adagene") (Nasdaq: ADAG),a platform-driven,clinical-stage biotechnology company transforming the discovery and development of novel antibody-based therapies,today announced the company's participation in several upcoming investor and scientific conferences.
Adagene's management will review recent clinical data demonstrating the best-in-class safety and efficacy profile for its masked anti-CTLA-4 candidate,ADG126. Details include:
Morgan Stanley 21st Annual Global Healthcare Conference
Date: Monday,September 11,2023
Fireside Chat Time: 4:15 PM-4:45 PM ET
Management will participate in investor meetings and a Fireside Chat,for which a live audio webcast and replay will be accessible in the Investors section of the company's website here.
H.C. Wainwright 25th Annual Global Investment Conference
Date: Wednesday,September 13,2023
Fireside Chat Time: 12:00 PM-12:30 PM ET
Management will participate in investor meetings and a Fireside Chat during the conference.
Society for Immunotherapy of Cancer (SITC) Webinar "Modulation of Tregs in Clinical Trials"
Date: Friday,September 22,2023
Presentation Time: 12:00 PM-2:00 PM ET
Featuring a group of distinguished speakers,this webinar will focus on CTLA-4 mediated regulatoryT cells (Tregs) and their essential role in anti-cancer therapy. Part of the series "Targets for Cancer IO: A Deep Dive," the full agenda and registration details are available here.
AboutAdagene
Adagene Inc.(Nasdaq: ADAG) is a platform-driven,clinical-stage biotechnology company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies.Adagenecombines computational biology and artificial intelligence to design novel antibodies that address unmet patient needs. Powered by its proprietaryDynamic Precision Library(DPL) platform,composed of NEObody™,SAFEbody®,and POWERbody™ technologies,Adagene's highly differentiated pipeline features novel immunotherapy programs.Adagenehas forged strategic collaborations with reputable global partners that leverage its technology in multiple approaches at the vanguard of science.
For more information,please visit:https://investor.adagene.com. FollowAdageneon WeChat,LinkedIn and Twitter.
SAFEbody®is a registered trademark inthe United States,Australia,Japan,Singapore,and theEuropean Union.
